Navigation Links
ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
Date:8/7/2008

second quarter ended June 30, 2008, were $0.8 million, as compared to $0.6 million in the second quarter of 2007.

At June 30, 2008, ISTA had cash and short-term investments of $21.8 million and long-term investments in auction rate securities of $4.4 million.

At June 30, 2008, ISTA reclassified the indebtedness under its convertible notes from a long term liability to a current liability as a result of the note holders right to require the Company to redeem the principal amount of the convertible notes at anytime on or after June 22, 2009.

Reconfirming 2008 Financial Outlook

-- We continue to expect our full-year 2008 net revenue will be approximately $75 to $82 million.

-- We continue to expect our full-year 2008 gross margin will be approximately 70% to 73%, subject to quarterly fluctuations based on revenue mix.

-- Depending upon the progress of our clinical and pre-clinical programs, we continue to expect that our research and development expenses for the full year of 2008 will be approximately $34 to $38 million, including stock-based compensation expense, which we continue to estimate will be approximately $0.5 to $1 million.

-- We continue to anticipate that our selling, general, and administrative expenses for the full-year 2008 will be approximately $50 to $54 million, including stock-based compensation expense, which we continue to estimate will be approximately $3.5 to $4.5 million.

Conference Call

ISTA will host a conference call with a simultaneous webcast today, August 7, 2008, at 5:00 PM Eastern Time, to discuss its second quarter 2008 results. To access the live conference call, U.S. and Canadian participants may dial 866-314-5232; international participants may dial 617-213-8052. The access code for the live call is 15676858. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... City, CA (PRWEB) August 28, 2014 ... sanitation products for the food processing industry, is asking ... a side-by side comparison of the E2 soap they’re ... E2 Sanitizing Foam Soap . Hand hygiene is ... in the food processing environment. Six key criteria are ...
(Date:8/28/2014)... LAFAYETTE, Ind. A new research platform ... properties of tiny structures undergoing stress and ... to improve designs for microelectronics and batteries., ... reveals information about how heating and the ... mechanical properties. Researchers have discussed the merits ...
(Date:8/28/2014)... The ability for organizations to attract ... allow individuals to perform at the highest of levels, ... looking to compete in this post–recession era. The ... as the sector increasingly focuses on the importance of ... have real results on the organization's development and the ...
(Date:8/28/2014)... Kent, WA (PRWEB) August 28, 2014 ... Synder Filtration’s polymeric membranes to its stable of ... of available molecular weight cut-offs and include membrane filters ... a steady increase in customer demand for our membrane ... a greater variety of flat sheet membranes,” explains Sterlitech ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2
... May 17, 2011 Brian Olson didn,t exactly fit the image ... be the first to admit it. "I had just a GED ... into remedial math." With a vague notion that he ... of," Olson enrolled in basic chemistry and biology courses as a ...
... May 17, 2011 P f enex ... has submitted a Biologics Master File (BMF) to the United ... carrier protein to support the development of conjugate vaccine products ... supplying cGMP grade CRM197 carrier protein to multiple partners in ...
... Mich., May 17, 2011 Neogen Corporation (Nasdaq: ... retired senior vice president of The Kroger Co. and former ... elected to Neogen,s Board of Directors. "Since our ... quality of individuals on our Board of Directors, and the ...
Cached Biology Technology:From GED to PhD: Borough of Manhattan Community College's Brian Olson Faces Academic Deficits Only to Be Rewarded with Acceptance to CUNY's PhD Program in Biochemistry 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3William T. Boehm Joins Neogen's Board of Directors 2
(Date:8/28/2014)... than traditional cigarettes, but still release toxins into ... USC. , Scientists studying secondhand smoke from e-cigarettes ... harmful particles, with close-to-zero exposure to organic carcinogens. ... in second-hand e-cigarette smoke were found to be ... levels of polycyclic aromatic hydrocarbons cancer-causing organic ...
(Date:8/28/2014)... researcher and his collaborators have developed an online analytic ... of re-engineering cells for biomedical investigation. CellNet is a ... aid stem cell engineering. Details of CellNet and its ... back-to-back papers in the journal Cell . , ... for all types of cell-based investigations and can potentially ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Genetics Society of America,s 27th Annual Mouse Molecular ... 2014 in Pacific Grove, California. These awards ... post doctorates and scientists from underrepresented groups into ... to encourage the participation of young scientists at ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2New tool aids stem cell engineering for medical research 2
... to be launched on Tuesday 14 February at the Lions ... hundreds of Victorians a year by extending the time between ... the new facilities, LCDS can now store corneas at human ... Previously, corneas were held at low temperatures and had to ...
... at improving the prevention, diagnosis and treatment of cancer, ... launched this week after several years of meticulous planning. ... south Manchester area are being given the opportunity to ... year. , They are being sent invitations to take ...
... director at the Max Planck Institute of Biochemistry in ... 1990s that blocking blood vessel development in a tumour ... fundamental principle led to the development of SUTENT®, whose ... clinical use in the United States, and it is ...
Cached Biology News:Australian first to save sight 2Multi-million pound UK Biobank underway 2Multi-million pound UK Biobank underway 3Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4
... Microarray Hybridization Wash Pack provides optimized ... slides. Preparation Quality Clarifier: Ready-to-use wash ... with SigmaScreen(tm) APS Coated Slides for ... Microarray Hybridization Blocking Buffer: 1L • ...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: